Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 5, 2018. The document serves as a report of a London Stock Exchange (LSE) announcement regarding positive clinical study outcomes for Nucala (mepolizumab), a biologic treatment for severe eosinophilic asthma. The announcement was issued on March 5, 2018, following the presentation of results at the American Academy of Allergy, Asthma & Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical update and does not contain financial statements or performance metrics for the reporting period.
Material Changes and Clinical Outcomes
The filing details significant clinical improvements observed in the OSMO study, an open-label, single-arm trial involving 145 patients with severe asthma uncontrolled on Xolair (omalizumab) who were switched to Nucala (mepolizumab). Key outcomes compared to baseline include:
- Asthma Control: Met the primary endpoint with a mean change from baseline of -1.45 on the Asthma Control Questionnaire (ACQ-5) at week 32.
- Exacerbations: Rate of exacerbations requiring oral steroids reduced by 64% (from 3.26 to 1.18 per patient-year).
- Hospitalizations: Rate of exacerbations requiring an ED visit or hospitalization reduced by 69% (from 0.63 to 0.19 per patient-year).
- Lung Function: Improvement in pre-bronchodilator FEV1 of 159 mL.
- Quality of Life: Improvement of -19 units on the SGRQ (compared to a Minimal Clinically Important Difference of -4.0).
- Biomarkers: Reduction in blood eosinophils of approximately 80% by Week 4, sustained through Week 32.
Additionally, a post-hoc meta-analysis of the MENSA and MUSCA studies showed Nucala provided early and sustained improvements in morning peak expiratory flow (AM PEF) compared to placebo (mean change of 26 L/min vs 4 L/min at the end of the observational period).
Guidance, Outlook, and Risks
Management Commentary: GSK management emphasized that the OSMO study provides evidence supporting the use of mepolizumab for complex patients eligible for both omalizumab and mepolizumab who are not well-controlled by omalizumab. The company highlighted Nucala as a market-leading biologic with a broad portfolio of respiratory treatments.
Regulatory Status: Nucala 100mg is approved in over 40 countries (including the EU, US, and Japan) for severe eosinophilic asthma. Nucala 300mg is approved in the US for eosinophilic granulomatosis with polyangiitis (EGPA). An sBLA has been filed for COPD treatment.
Risks and Safety: The filing includes standard safety warnings for Nucala, including hypersensitivity reactions (anaphylaxis, angioedema), the risk of herpes zoster, and the need to treat pre-existing parasitic infections. It explicitly states Nucala is not for acute asthma symptoms. A cautionary statement notes that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.
Investor Verification Checklist
- Verify the commercial impact of the OSMO study results on Nucala's market share against competitors like Xolair.
- Confirm the timeline and regulatory status of the sBLA for COPD treatment mentioned in the filing.
- Review the full prescribing information for Nucala regarding safety profiles and contraindications.
- Check subsequent quarterly reports for any financial updates related to the Respiratory franchise performance.
- Monitor for any new safety data or post-marketing surveillance reports regarding Nucala.